Your browser doesn't support javascript.
loading
Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer.
Vokes, E E; Haraf, D J; Panje, W R; Schilsky, R L; Weichselbaum, R R.
Affiliation
  • Vokes EE; Department of Medicine, The University of Chicago Medical Center, IL 60637-1470.
Semin Oncol ; 19(3 Suppl 9): 53-8, 1992 Jun.
Article in En | MEDLINE | ID: mdl-1641658
ABSTRACT
Hydroxyurea is an active single agent in squamous cell cancer of the head and neck. It has been used clinically, most frequently as a radiation-enhancing agent with concomitant radiotherapy. Pilot trials testing hydroxyurea in this setting reported encouraging results. Two randomized trials have been conducted with inconclusive results, possibly relating to study cohort size and short period of follow-up. More recently, hydroxyurea has been investigated with 5-fluorouracil and concomitant radiotherapy. A sound theoretic rationale can be made for this approach and data derived from a phase I/II study are presented. These support the further investigation of this regimen.
Subject(s)
Search on Google
Database: MEDLINE Main subject: Radiation-Sensitizing Agents / Carcinoma, Squamous Cell / Fluorouracil / Head and Neck Neoplasms / Hydroxyurea Type of study: Clinical_trials Limits: Humans Language: En Year: 1992 Type: Article
Search on Google
Database: MEDLINE Main subject: Radiation-Sensitizing Agents / Carcinoma, Squamous Cell / Fluorouracil / Head and Neck Neoplasms / Hydroxyurea Type of study: Clinical_trials Limits: Humans Language: En Year: 1992 Type: Article